Amneal Pharmaceuticals, Inc. AMRX R2K
Company Overview
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Why Investors Should Care
Net profit has compounded at 51.8% per year over the last five years.
Revenue has grown at a 10.9% CAGR over the past five years.
Operating margin of 19.6% supports profitability.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $3.02B (+8.0% YoY); net profit $72.06M.
- Trailing 12 Months Year-on-year growth — revenue +3.9%, earnings +384.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.9%, profit CAGR 51.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.92% |
| 1 Year: | 3.90% |
Compounded Profit Growth
| 5 Years: | 51.81% |
| 1 Year: | 384.60% |
Stock Price Performance
| 1 Year: | +104.28% |
| 6 Months: | +32.51% |
| 3 Months: | +31.10% |
| 1 Month: | +6.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)65.49 · Neutral
P/E of 46.49 is above the sector median of 25.88 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.9% over 5 years.
- Profit CAGR of 51.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AMRX Amneal Pharmaceuticals, Inc. R2K | 17.20 | 46.49 | $5.49B | 0.00% | 13.60% | -101.78% | 10.92% | 51.81% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 225.68M | 259.87M | 254.73M | 293.37M | 275.19M | 413.79M | 476.49M | 497.53M | 446.12M | 404.64M | 378.28M | 397.33M | 498.53M | 464.66M | 519.29M | 493.11M | 535.08M | 528.59M | 497.63M | 559.36M | 545.56M | 557.54M | 599.05M | 620.04M | 659.19M | 701.78M | - | - | 695.42M | 724.51M | 784.51M | 814.32M | 722.52M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 439.53M | 438.25M | 510.54M | 517.13M | 402.41M |
| Gross Profit | 116.02M | 123.73M | 135.01M | 151.42M | 144.59M | 178.29M | 200.10M | 193.41M | 83.08M | 105.25M | 54.43M | 110.23M | 183.50M | 144.24M | 133.59M | 191.56M | 212.50M | 198.51M | 174.57M | 200.52M | 194.23M | 178.19M | 220.02M | 232.53M | 238.06M | 249.95M | - | - | 255.89M | 286.25M | 273.97M | 297.19M | 320.11M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154.97M | 174.25M | 203.49M | 182.69M | 171.84M |
| Operating Income | - | 44.60M | 78.75M | - | 63.55M | -181.06M | 74.56M | - | -94.36M | -18.91M | -112.27M | - | 57.79M | 10.75M | 2.44M | 45.91M | 67.12M | 28.52M | 23.30M | -198.62M | 44.35M | 34.45M | 80.08M | 75.65M | -10.75M | 95.47M | - | - | 100.92M | 112.01M | 70.49M | 114.50M | 148.27M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154.58M | 176.93M | 111.66M | 160.70M | 176.73M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.94M | 65.10M | 62.81M | 56.24M | 53.36M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 37.49M | 51.71M | -5.22M | 55.23M | 80.18M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.87M | 16.10M | -23.36M | 5.66M | 2.18M |
| Net Income | - | 0 | 0 | 0 | 0 | -17.86M | 6.89M | - | -47.88M | -16.90M | -265.01M | - | 120.43M | -24.16M | -21.64M | 12.75M | 29.99M | -7.78M | -8.82M | -242.13M | -7.61M | -6.94M | 11.92M | 9.68M | -91.64M | 5.99M | - | - | 12.20M | 22.42M | 2.37M | 35.08M | 62.26M |
| Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.15 | 0.05 | -0.07 | -0.37 | -0.13 | -2.03 | -0.23 | 0.78 | -0.08 | -0.06 | 0.04 | 0.10 | -0.03 | -0.01 | -0.80 | -0.02 | -0.05 | 0.08 | 0.06 | -0.30 | 0.02 | - | - | 0.04 | 0.07 | 0.01 | 0.11 | 0.19 |
| R&D Expense | - | 47.18M | 41.32M | - | 44.21M | 50.34M | 42.35M | - | 53.86M | 48.02M | 38.12M | - | 36.38M | 45.57M | 44.52M | 48.18M | 52.86M | 48.93M | 52.80M | 50.75M | 50.23M | 38.69M | 37.80M | 41.38M | 39.30M | 36.05M | 61.10M | - | 40.04M | 47.96M | 63.35M | - | 38.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.02B | 1.03B | 1.66B | 1.63B | 1.99B | - | 2.21B | 2.39B | 2.79B | 3.02B |
| Cost of Revenue | - | - | - | - | - | - | 1.43B | 1.57B | 1.77B | 1.91B |
| Gross Profit | 597.46M | 526.18M | 716.40M | 353.00M | 628.39M | - | 784.71M | 820.57M | 1.02B | 1.11B |
| Operating Expenses | - | - | - | - | - | - | 595.79M | 581.82M | 672.07M | 715.39M |
| Operating Income | 284.88M | 245.10M | -19.67M | -248.68M | 91.16M | - | 188.92M | 238.75M | 348.37M | 397.91M |
| EBITDA | - | - | - | - | - | - | 150.43M | 399.76M | 439.77M | 603.87M |
| Interest Expense | - | - | - | - | - | - | 158.38M | 210.63M | 258.60M | 241.09M |
| Pretax Income | - | - | - | - | - | - | -248.13M | -40.27M | -55.01M | 139.21M |
| Tax Provision | - | - | - | - | - | - | 6.66M | 8.45M | 18.86M | 11.28M |
| Net Income | 0 | 0 | -19.74M | -603.57M | 67.79M | - | -129.99M | -83.99M | -116.89M | 72.06M |
| Diluted EPS | - | - | -0.16 | -2.74 | 0.61 | - | -0.86 | -0.48 | -0.38 | 0.22 |
| R&D Expense | 179.02M | 171.42M | 194.19M | 188.05M | 179.93M | 201.85M | 195.69M | 163.95M | 190.71M | 186.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Oct 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.34B | 4.35B | 3.67B | 4.01B | - | 3.80B | 3.47B | 3.50B | 3.68B |
| Current Assets | - | - | - | - | - | - | - | 1.41B | 1.38B | 1.59B | 1.91B |
| Cash & Equivalents | 27.37M | 0 | 74.17M | 213.39M | 151.20M | 341.38M | - | 25.98M | 91.54M | 110.55M | 282.03M |
| Inventory | - | - | - | - | - | - | - | 530.74M | 581.38M | 612.45M | 606.30M |
| Receivables | - | - | - | - | - | - | - | 741.79M | 613.73M | 775.73M | 895.14M |
| Total Liabilities | - | - | 0 | - | - | - | - | 3.62B | 3.45B | 3.61B | 3.75B |
| Current Liabilities | - | - | 296.88M | 553.85M | 550.41M | 676.90M | - | 752.80M | 846.60M | 1.13B | 881.63M |
| Long Term Debt | - | - | 1.36B | 2.63B | 2.61B | 2.74B | - | 2.63B | 2.43B | 2.16B | 2.57B |
| Total Debt | - | - | - | - | - | - | - | 2.85B | 2.75B | 2.59B | 2.69B |
| Total Equity | - | 0 | 0 | 504.75M | 232.01M | 303.27M | - | 298.42M | 19.78M | -109.27M | -70.79M |
| Shares Outstanding | - | - | - | - | - | - | - | 151.49M | 306.56M | 309.88M | 314.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 115.06M | 234.19M | 250.23M | 1.71M | 379.00M | - | 65.10M | 345.58M | 295.10M | 339.99M |
| Investing Cash Flow | -124.61M | -98.55M | -396.38M | -19.58M | -317.55M | - | -174.31M | -69.19M | -63.00M | -112.26M |
| Financing Cash Flow | -19.50M | -95.02M | 287.68M | -45.83M | 131.81M | - | -106.62M | -212.57M | -211.79M | -31.53M |
| Capital Expenditure | -122.76M | -94.77M | -83.09M | -47.18M | -56.45M | - | -90.59M | -69.19M | -74.99M | -114.36M |
| Free Cash Flow | -7.70M | 139.42M | 167.14M | -45.48M | 322.56M | - | -25.50M | 276.39M | 220.11M | 225.63M |
| Net Change in Cash | - | - | - | - | - | - | -215.83M | 63.81M | 20.31M | 196.20M |
| Dividends Paid | 200.62M | 375.26M | 183.00M | 0 | 0 | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 58.7% | 50.9% | 43.1% | 21.7% | 31.5% | - | 35.5% | 34.3% | 36.5% | 36.9% |
| Operating Margin % | 28.0% | 23.7% | -1.2% | -15.3% | 4.6% | - | 8.5% | 10.0% | 12.5% | 13.2% |
| Net Margin % | 0.0% | 0.0% | -1.2% | -37.1% | 3.4% | - | -5.9% | -3.5% | -4.2% | 2.4% |
| ROE % | - | - | -3.9% | -260.1% | 22.4% | - | -43.6% | -424.6% | 107.0% | -101.8% |
| ROCE % | - | 23.5% | -0.5% | -8.0% | 2.7% | - | 6.2% | 9.1% | 14.7% | 14.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.00% | 24.52M | $409.23M |
| 2 | TPG GP A, LLC | 4.02% | 12.33M | $205.77M |
| 3 | Vanguard Portfolio Management LLC | 3.69% | 11.32M | $189.01M |
| 4 | Rubric Capital Management LP | 3.60% | 11.04M | $184.22M |
| 5 | Vanguard Capital Management LLC | 2.47% | 7.59M | $126.59M |
| 6 | State Street Corporation | 2.22% | 6.79M | $113.40M |
| 7 | Dimensional Fund Advisors LP | 1.86% | 5.69M | $94.98M |
| 8 | Morgan Stanley | 1.51% | 4.64M | $77.39M |
| 9 | Geode Capital Management, LLC | 1.48% | 4.55M | $75.87M |
| 10 | Neuberger Berman Group, LLC | 1.20% | 3.68M | $61.46M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AMRX
3 Reasons AMRX is Risky and 1 Stock to Buy Instead
Amneal currently trades at $16.70 and has been a dream stock for shareholders. It’s returned 283% since July 2021, blowing past the S&P 500’s 72.3% gain. The company has also beaten the index over the past six months as its stock price is u…
Amneal to Report Second Quarter 2026 Results on July 30, 2026
BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market ope…
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amneal (NASDAQ:AMRX) and its peers.
1 Mooning Stock Worth Your Attention and 2 We Question
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.…
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopaHopledo® is already approved and marketed i…
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.…
AMRX — Frequently Asked Questions
What is the current share price of Amneal Pharmaceuticals, Inc. (AMRX)?
As of 2026-07-15 16:51 PDT, Amneal Pharmaceuticals, Inc. (AMRX) trades at $17.20 on NasdaqGS. Its 52-week range is $7.82 to $17.32.
What is the market capitalisation of AMRX?
Amneal Pharmaceuticals, Inc. (AMRX) has a market capitalisation of $5.49B on NasdaqGS.
What is the P/E ratio of AMRX?
AMRX trades at a trailing price-to-earnings (P/E) ratio of 46.49. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is -117.54.
What is the return on equity (ROE) of AMRX?
AMRX has a return on equity (ROE) of -101.78%. Its return on capital employed (ROCE) is 13.60%.
Is AMRX a good stock to buy?
This page provides a data-driven analysis of Amneal Pharmaceuticals, Inc. (AMRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.